Astellas Pharma Inc.
Stock Price Chart
2026/11/09 12:01 UpdatedPrice Trend
2026/11/09 12:01 UpdatedPrice & Trading Details
2026/11/09 12:01 UpdatedPRICE
TRADING
Analyst Recommendations 13 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/05 | ¥50.96 | ¥79.15 | +55.3% |
| 2026/04/27 | ¥21.44 | ¥24.29 | +13.3% |
| 2026/02/04 | ¥42.44 | ¥56.04 | +32.0% |
| 2025/10/29 | ¥28.86 | ¥44.22 | +53.3% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
26.4M | +0.94% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
17.5M | +1.22% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
13.1M | +1.32% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
7.7M | +3.43% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
6.7M | +0.80% | |
|
iShares Trust-iShares MSCI EAFE ETF
|
6.2M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
2.9M | +34.28% | |
|
Paradigm Asset Management Company, LLC
|
5.1K | 0.00% |
Dividend History 4Years Growth
Updated 2026/11/08| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥79 | +3.9% |
| 2025 | ¥76 | +5.6% |
| 2024 | ¥72 | +10.8% |
| 2023 | ¥65 | +18.2% |
| 2022 | ¥55 | - |
Financial Performance
2026/11/08 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,296,163M | ¥1,518,619M | ¥1,603,672M | ¥1,912,323M |
| Gross Profit | ¥1,043,154M | ¥1,230,266M | ¥1,311,187M | ¥1,563,117M |
| Operating Income | ¥130,963M | ¥131,557M | ¥18,947M | ¥40,248M |
| Pretax Income | ¥161,835M | ¥141,140M | ¥36,974M | ¥48,914M |
| Net Income | ¥124,086M | ¥98,714M | ¥17,045M | ¥50,747M |
| EPS | ¥67.05 | ¥54.09 | ¥9.47 | ¥28.24 |
| Operating Margin | 10.10% | 8.66% | 1.18% | 2.10% |
| Balance Sheet | ||||
| Total Assets | ¥2,332,395M | ¥2,456,518M | ¥3,569,603M | ¥3,339,544M |
| Total Equity | ¥1,460,308M | ¥1,507,954M | ¥1,595,988M | ¥1,513,255M |
| Total Liabilities | ¥872,087M | ¥948,564M | ¥1,973,615M | ¥1,826,289M |
| Cash | ¥315,986M | ¥376,840M | ¥335,687M | ¥188,372M |
| Interest-bearing Debt | - | ¥125,000M | ¥920,016M | ¥831,426M |
| Equity Ratio | 62.61% | 61.39% | 44.71% | 45.31% |
| D/E Ratio | 0.00 | 0.08 | 0.58 | 0.55 |
| Cash Flow | ||||
| Operating CF | ¥257,444M | ¥327,767M | ¥172,475M | ¥194,512M |
| Investing CF | -¥62,413M | -¥84,500M | -¥845,802M | -¥89,419M |
| Financing CF | -¥216,298M | -¥195,623M | ¥614,060M | -¥261,367M |
| Free CF | ¥180,996M | ¥239,226M | ¥89,978M | ¥137,182M |
| Efficiency | ||||
| ROE | 8.50% | 6.55% | 1.07% | 3.35% |
| ROA | 5.32% | 4.02% | 0.48% | 1.52% |
Latest IR Information
-
Unknown
Provides supplemental IFRS materials for the second quarter of the fiscal year ending March 2027. Discloses cumulative-period and quarterly revenue, operating income, interim profit, earnings per share, and sales by region and major products. Some indicators suggest potential revisions to...
Read more -
Fiscal 2026 Q2 Consolidated Financial Summary
Revenue increased 23% year-over-year, core operating profit increased 50% year-over-year. Full-year guidance was revised upward: revenue +110 billion yen, core operating profit +80 billion yen. Targeting a 30% core operating profit margin. Pipeline advances include PADCEV, IZERVAY, VYLOY and progress...
Read more -
Financial Summary for the Six Months Ended March 2027 (IFRS) (Consolidated)
Revenue was approximately 1,270,861 million yen, up 23.4% year-over-year. Core operating income was approximately 424,928 million yen, and core interim profit was approximately 331,499 million yen, both showing substantial increases. Full-year guidance was revised upward on a core basis to...
Read more -
FY2026 Q1 Consolidated Financial Results
The FY2026 Q1 consolidated results indicate likely revenue growth and earnings improvement. Highlights include growth in net sales, core operating income, and quarterly profit. Progress in the pipeline and steady growth of key products are cited as factors supporting continued...
Read more -
Q1 FY2027 Financial Results Supplement
IFRS-based consolidated results supplement for the first quarter of the fiscal year ending March 2027. Net sales increased year over year; full-year guidance revised to 22,200 billion yen with YoY change indicated. Includes breakdown by key products and regions, currency...
Read more -
FY2027 First Quarter IFRS (Consolidated) Financial Summary
Net sales 640,914 million yen (up 26.7% YoY), Core operating profit 221,417 million yen (up 55.6%), Core quarterly profit 170,472 million yen (up 62.8%). Full-year forecast for 2027: net sales 2,220,000 million yen, core operating profit 620,000 million yen, core...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥2,536
Rating Score: 2.43 (Based on 13 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
